A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab plus daratumumab and dexamethasone (Dd) which will be administered to participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.

Trial Details

NCT ID
NCT04910568
Phase
PHASE1
Sponsor
Genentech, Inc.
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Cevostamab
  • Tocilizumab
  • Pomalidomide
  • Daratumumab
  • Dexamethasone
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Irvine, California, United States|33.66946,-117.82311
  • Denver, Colorado, United States|39.73915,-104.9847
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Detroit, Michigan, United States|42.33143,-83.04575

Key Eligibility Criteria

  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  • Life expectancy of at least 12 weeks
  • Agreement to provide bone marrow biopsy and aspirate samples
  • Resolution of adverse events from prior anti-cancer therapy to Grade \<=1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →